Genetic involvement in the pathogenesis of neurological disease is significant. Central nervous system disorders account for approximately 60 percent of the 6,400 phenotypic entries in cataloged inherited human diseases. Neurological diseases, especially brain diseases, are the last frontier in medical discovery. Advances in testing such as next-generation sequencing have been instrumental in identifying genetic causes for neurological conditions.
The area of inherited condition testing for neurological conditions has become a major area of activity in the last decade or so, coinciding with the acceleration of sequencing and other technologies. Increasing awareness of neurological disorders, the aging population, and continued advancements in medical genetics will likely drive the neurological genetic testing market.
This report Genetic Testing Markets for Epilepsy, Autism, Alzheimer’s and Other Neurologic Conditions focuses on the neurological segments of the inherited/ genetic disease testing market, including autism, Alzheimer’s disease and other neurological diseases. Next-generation sequencing has provided new abilities in recent years to affordably produce much larger volumes of sequence. It offers the choice of single genes, panels, exomes and other methods.
As part of its coverage, this report provides:
Overview of Market
Selected Companies and Products in the Neurological Genetic Testing Market
Genetic Neurological Testing 2020-2025 (in $ millions)
Genetic Testing by Disease Type (Autism, Alzheimer’s and other Neurological Diseases) 2020-2025 (in $ millions)
COVID-19 Impact
Companies in the Market
Company profiled in the report include:
Ambry Genetics
Arup Laboratories
Asuragen
Athena Diagnostics
Blueprint Genetics
Centogene AG
Cytox Group Limited
Fulgent Genetics
Genedx
Illumina
Invitae
Laboratory Corporation of America
Lineagen
PerkinElmer
Quest
Thermo Fisher Scientific
Table of Contents
CHAPTER 1: EXECUTIVE SUMMARY
OVERVIEW
SCOPE AND METHODOLOGY
MARKET OVERVIEW AND POTENTIAL
Table 1-1: Genetic Neurological Testing 2020-2025 (in $ millions)
COVID-19 IMPACT
CHAPTER 2: INTRODUCTION
OVERVIEW
Autism
Alzheimer’s Disease
Other Neurological Diseases
Types of Testing
Limitations in Exome Sequencing
Costs of Exome Sequencing
Areas of Difficulty for NGS to Penetrate Market
Role of FISH/ISH
De Novo Mutations Not Excluded
CHAPTER 3: PRODUCTS AND MARKET POTENTIAL
GENETIC TESTING FOR AUTISM
GENETIC TESTING FOR ALZHEIMER’S DISEASE
GENETIC TESTING FOR OTHER SELECT NEUROLOGICAL DISEASES
Table 3-1: Selected Companies and Products in the Neurological Genetic Testing Market
MARKET REVENUE AND FORECAST
Table 3-2: Genetic Neurological Testing 2020-2025 (in $ millions)
Table 3-3: Genetic Testing by Disease Type Autism, Alzheimer’s and other Neurological Diseases 2020-2025 (in $ millions)
